Edwards Lifesciences (NYSE:EW) updated its FY19 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $5.05-5.30 for the period, compared to the Thomson Reuters consensus estimate of $5.19. The company issued revenue guidance of $3.9-4.3 billion, compared to the consensus revenue estimate of $4.16 billion.Edwards Lifesciences also updated its FY18 guidance to $4.60-4.75 EPS.
A number of research firms have recently weighed in on EW. Raymond James increased their target price on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the stock an outperform rating in a report on Thursday. Bank of America lowered shares of Edwards Lifesciences from a buy rating to a neutral rating in a report on Tuesday, October 2nd. ValuEngine upgraded shares of Edwards Lifesciences from a hold rating to a buy rating in a report on Wednesday, September 19th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the stock an overweight rating in a report on Friday. Finally, SunTrust Banks dropped their target price on shares of Edwards Lifesciences to $170.00 and set a buy rating for the company in a report on Friday, August 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $162.85.
Shares of EW opened at $157.21 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18. Edwards Lifesciences has a one year low of $110.68 and a one year high of $175.00. The stock has a market capitalization of $34.14 billion, a price-to-earnings ratio of 41.37, a P/E/G ratio of 2.15 and a beta of 0.90.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. During the same period last year, the business posted $0.84 earnings per share. Edwards Lifesciences’s quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences will post 4.7 EPS for the current fiscal year.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $142.64, for a total transaction of $99,848.00. Following the completion of the transaction, the vice president now owns 27,772 shares of the company’s stock, valued at $3,961,398.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction that occurred on Monday, October 29th. The shares were sold at an average price of $140.74, for a total transaction of $4,630,346.00. The disclosure for this sale can be found here. Insiders sold 187,156 shares of company stock valued at $27,603,513 over the last 90 days. 1.84% of the stock is currently owned by company insiders.
WARNING: “Edwards Lifesciences (EW) Releases FY19 Earnings Guidance” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2018/12/08/edwards-lifesciences-ew-releases-fy19-earnings-guidance.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Story: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.